RxDoctor Payments DataLook up a doctor →

Alvaro Aranda Rodriguez, MD

Pulmonary Disease · Guaynabo, PRNPI 1972587970

Payments from drug & device makers

$1,860,489in general payments, 2019–2025

Across 1,476 payments — averaging $1260.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$293K
  • Bayer$190K
  • Boehringer Ingelheim$175K
  • United Therapeutics Corporation$158K
  • GSK$138K
  • Actelion Pharmaceuticals US, Inc.$120K
  • plus $786K from 38 others
$361in research payments, 2019–2025

Across 1 payment — averaging $360.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$361

What the payments were for

  • Consulting fees$41,4186%
  • Speaking & faculty fees$619,15085%
  • Travel & lodging$31,3044%
  • Food & beverage$31,9374%
  • Education$7110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,860,489 in reported general payments places this provider in the 95th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$78,258
Medicare patients
177
Services billed
1,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat942$12,599,986
OpsumitMacitentan674$8,535,776
Tyvaso DpiTreprostinil159$3,656,135
UptraviSelexipag65$1,535,404
OfevNintedanib Esylate85$1,076,328
Orenitram ErTreprostinil Diolamine60$941,221
OpsynviMacitentan/Tadalafil30$378,605
EsbrietPirfenidone35$367,031
Trelegy ElliptaFluticasone/Umeclidin/Vilanter475$320,228
Dupixent SyringeDupilumab53$201,246
LetairisAmbrisentan12$155,611
Spiriva RespimatTiotropium Bromide289$155,186
Dupixent PenDupilumab39$148,254
Pirfenidone56$123,261
Ambrisentan69$114,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$190,464$12,599,986942 claims
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi$120,235$10,449,786769 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$175,041$1,259,632432 claims
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta$137,610$522,512840 claims
Genentech USA, Inc.Esbriet$16,735$367,03135 claims
GileadLetairis$41$155,61112 claims
AstraZenecaSymbicort, Breztri Aerosphere$84,884$92,681302 claims
Johnson & JohnsonXarelto$569$7,72514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Guaynabo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →